CD274 and sarcoma: High tumor mutational burden (TMB), tumor PD-L1 (CD274) expression, and increased tumor-infiltrating lymphocytes (TIL) are biomarkers of response to checkpoint inhibitors in multiple cancer types that have been found to be low across most sarcoma subtypes11,12.